Contiflo Icon 0.4 Mg Tablet PR

Contiflo Icon 0.4 Mg Tablet PR (Tamsulosin Hydrochloride)

Contiflo Icon 0.4 Mg Tablet PR is a high-potency pharmacological intervention containing Tamsulosin Hydrochloride, a selective alpha-1 adrenoceptor antagonist specifically engineered for the clinical management of functional symptoms associated with Benign Prostatic Hyperplasia (BPH). Utilizing a unique “Prolonged-Release” (PR) delivery system, this formulation works by concurrently modulating the smooth muscle tension in the prostatic urethra and the bladder neck. By neutralizing the biochemical triggers of localized muscular constriction and facilitating the organized relaxation of the prostate gland tissues, Contiflo Icon effectively promotes an immediate increase in urinary flow rates and a reduction in obstructive symptoms. This targeted biochemical action provides a decisive therapeutic response by reinforcing the structural uniformity of the urinary passage and promoting a stable, physiological recovery from lower urinary tract stressors.

Key Features

• Specifically formulated with Tamsulosin to target the alpha-1A and alpha-1D receptors located within the prostatic and bladder smooth muscle.
• Clinically recognized for its role in facilitating the natural optimization of urinary flow and reducing post-void residual volume.
• Specifically engineered to reach therapeutic levels steadily over a 24-hour period, ensuring a robust defense against nocturnal frequency.
• Acts as a functional catalyst to stabilize the bladder function and support the reduction of urgency and hesitancy.
• Formulated to address localized BPH symptoms with minimal impact on systemic blood pressure compared to non-selective antagonists.

Key Ingredients

• Tamsulosin Hydrochloride (0.4 mg)
• Hypromellose (HPMC)
• Microcrystalline Cellulose
• Magnesium Stearate

Precautions

• This is a high-potency urological medication. Use must be strictly dictated by a healthcare professional after a formal clinical diagnosis of BPH.
• Be advised that temporary dizziness or postural hypotension may occur; exercise caution when rising from a seated or lying position.
• Patients scheduled for cataract or glaucoma surgery must inform their ophthalmic surgeon of Contiflo Icon use to prevent Intraoperative Floppy Iris Syndrome (IFIS).
• Consult with a specialist regarding potential interactions with other alpha-blockers or phosphodiesterase-5 (PDE5) inhibitors.
• This formulation is specifically indicated for male physiological requirements and is not intended for use in pediatric or female patient populations.
• Keep the blister pack tightly sealed and store in a cool, dry place (below 25°C). Protect from direct light to maintain the molecular stability of the active constituent.

How to Use

• The tablet should be swallowed whole with a glass of water. Do not crush, break, or chew the tablet to ensure the intended prolonged-release delivery.
• A single 0.4 mg tablet constitutes the standard daily therapeutic dose, unless otherwise specifically directed by a urologist.
• For optimal clinical results, administration should occur at the same time each day, preferably following the same meal (typically breakfast or dinner).
• Ensure consistent daily intake to maintain stable plasma concentrations and ensure the continuous relaxation of the prostatic smooth muscle.
• Use as a standalone urological treatment or as part of a comprehensive combination therapy for BPH as dictated by clinical requirements.
• Maintain a regular schedule to document visible improvements in urinary flow and the reduction of obstructive symptoms over a sustained period.

Legal Disclaimer: Contiflo Icon 0.4 Mg Tablet PR is a specialized pharmacological intervention for BPH symptoms. Individual results vary based on the patient’s baseline prostatic volume and physiological response. This product does not prevent prostate cancer and should be used only after appropriate clinical screening. This information is for educational purposes and is not a substitute for professional medical consultation or a formal clinical diagnosis.